Company Announcement no. 4/2016
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 30 March 2016
Veloxis increases share capital in connection with exercise of warrants
Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 21,722,966 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 2,172,296.60 as a consequence of the exercise of warrants by current and former employees of the company granted under the company's warrant program.
As a result of the employee’s investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 7,603,038 The subscription price for the new shares is DKK 0.35 per share of nominal DKK 0.10.
The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 168,550,654.10 divided into shares of DKK 0.10 each.
Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.
For more information, please contact:
Craig A. Collard Johnny Stilou
President & CEO EVP, Chief Financial Officer
Phone: +1 919 524 4317 Phone: +45 30 53 33 64
Email: cac@veloxis.com Email: jst@veloxis.com
Veloxis Pharmaceuticals A/S (VELO)
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis’ unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
